rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Weston Nichols

Director

Company insider

Files Form 4 as: Director, Crinetics Pharmaceuticals; 10% owner, Passage Bio; 10% owner, Korro Bio; 10% owner, Cullinan Therapeutics; 10% owner, TScan Therapeutics.

Every Form 4 they filed

In numbers

Trades disclosed
44
Buys
9
Sells
0
Bought
$2.2M
Sold
$0
Companies
5
Companies where not an officer
5
First trade
21 Jun 2019
Last trade
1 Sep 2026
Last filed
1 Sep 2026

Companies traded

Everywhere else they filed: board seats, 10% stakes, other companies
Crinetics PharmaceuticalsDirector · Biotechnology · last 1 Sep 20260 buys · 0 sells
PASG Passage Bio10% owner · Biotechnology · last 25 Jun 20264 buys · 0 sells
KRRO Korro Bio10% owner · Biotechnology · last 31 Mar 20261 buy · 0 sells
CGEM Cullinan Therapeutics10% owner · Biotechnology · last 28 Oct 20251 buy · 0 sells
TCRX TScan Therapeutics10% owner · Biotechnology · last 26 Dec 20243 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
03Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
1 Sep 2026filed 1 Sep 2026Crinetics PharmaceuticalsBiotechnologySEC FORM 4 Code D$1.4M16,300 at $85.00filing
1 Sep 2026filed 1 Sep 2026Crinetics Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D$478K9,730 at $49.13filing
1 Sep 2026filed 1 Sep 2026Crinetics PharmaceuticalsBiotechnologySEC FORM 4 Code D$504K5,925 at $85.00filing
1 Sep 2026filed 1 Sep 2026Crinetics Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D$772K12,500 at $61.76filing
1 Sep 2026filed 1 Sep 2026Crinetics Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D$772K12,500 at $61.76filing
1 Sep 2026filed 1 Sep 2026Crinetics Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D$772K12,500 at $61.77filing
1 Sep 2026filed 1 Sep 2026Crinetics Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D$1.1M17,500 at $64.77filing
1 Sep 2026filed 1 Sep 2026Crinetics Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D$1.2M17,500 at $66.71filing
1 Sep 2026filed 1 Sep 2026Crinetics Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D$1.1M17,500 at $64.68filing
1 Sep 2026filed 1 Sep 2026Crinetics Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D$504K12,500 at $40.29filing
1 Sep 2026filed 1 Sep 2026Crinetics Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D$545K10,350 at $52.67filing
1 Sep 2026filed 1 Sep 2026Crinetics Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D$478K9,730 at $49.13filing
1 Sep 2026filed 1 Sep 2026Crinetics Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D$772K12,500 at $61.77filing
1 Sep 2026filed 1 Sep 2026Crinetics Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D$1.1M17,500 at $64.77filing
1 Sep 2026filed 1 Sep 2026Crinetics Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D$1.2M17,500 at $66.71filing
1 Sep 2026filed 1 Sep 2026Crinetics Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D$1.1M17,500 at $64.68filing
1 Sep 2026filed 1 Sep 2026Crinetics Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D$504K12,500 at $40.29filing
1 Sep 2026filed 1 Sep 2026Crinetics Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code D$545K10,350 at $52.67filing
1 Sep 2026filed 1 Sep 2026Crinetics PharmaceuticalsBiotechnologySEC FORM 4 Code D$1.4M16,300 at $85.00filing
1 Sep 2026filed 1 Sep 2026Crinetics PharmaceuticalsBiotechnologySEC FORM 4 Code D$504K5,925 at $85.00filing

News

BioLineRx (NASDAQ:BLRX) and Korro Bio (NASDAQ:KRRO) Head to Head SurveyKRRO · dailypolitical.com · 14 Oct 2026Contrasting BioLineRx (NASDAQ:BLRX) & Korro Bio (NASDAQ:KRRO)KRRO · tickerreport.com · 14 Oct 2026

0 headlines in the last 90 days name Weston Nichols; 2 articles from the last 14 days about the 3 companies they traded most, at most three about any one of them.

Sectors

Health Care9

Buys in green, sells in red, by the company’s sector.

Related people

Jean Francois FormelaDirector · Director at Korro Bio, filing Form 4 there in the last year
Oliver DolanSenior Vice President, Finance · Senior Vice President, Finance at Korro Bio, filing Form 4 there in the last year
Jennifer MichaelsonChief Scientific Officer · Chief Scientific Officer at Cullinan Therapeutics, filing Form 4 there in the last year
Matthew K. FustDirector · Director at Crinetics Pharmaceuticals, filing Form 4 there in the last year
Wendell WierengaDirector · Director at Crinetics Pharmaceuticals, filing Form 4 there in the last year
Lynx1 Capital Management LP10% owner · Also traded KRRO in the last 90 days
Ram AiyarPresident and CEO · Also traded KRRO in the last 90 days